A number of biopharmaceutical companies listed on the Shenzhen Stock Exchange have released their semi-annual forecasts, with their research and development achievements helping to stabilize and improve their performance.

The performance forecasts for listed companies in the biopharmaceutical industry in the first half of 2025 have been successively released, with related companies showing stable and improving performance. As of July 25th, a total of 56 companies in the biopharmaceutical industry in the Shenzhen Stock Exchange have disclosed their performance forecasts for the first half of 2025, with a collective estimated net profit of 3.8 billion to 5 billion yuan. Among these listed companies, 3 companies have turned losses into profits, and 13 companies are expected to have a year-on-year increase in net profit of over 100%. From the perspective of reasons for performance growth, emphasis on research and development, new product launches, and increased sales volume are among the key factors driving the growth in performance for these companies.